Dyne: H2 2024 Muscle Disease Data Could Boost Value (NASDAQ:DYN)

Published on 5 Mar 2024 on Seeking Alpha

Dyne Therapeutics, Inc. results from DYNE-101 for the treatment of patients with Myotonic Dystrophy...

Read the rest of the article

Start tracking your investments with Statfolio

Shares of Landos Biopharma, Inc. LABP rose sharply during Monday’s session following acquisition...

Benzinga 25 Mar 2024

Stocks that are trading heavily or have substantial price changes on Monday: United Airlines, Dyn...

Washington Post 25 Mar 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of ...

Benzinga 25 Mar 2024

Muscle disease company Dyne Therapeutics (DYN) said on Monday that John Cox has been appointed pr...

Seeking Alpha 25 Mar 2024

Investing.com 25 Mar 2024

Dyne Therapeutics, Inc. results from DYNE-101 for the treatment of patients with Myotonic Dystrop...

Seeking Alpha 5 Mar 2024

Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of t...

GuruFocus.com via Yahoo Finance 2 Mar 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The ...

Benzinga 1 Mar 2024

In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For...

Insider Monkey via Yahoo Finance 29 Feb 2024

Jonathan Mcneill, Chief Business Officer of Dyne Therapeutics Inc (NASDAQ:DYN), executed a sale o...

GuruFocus.com via Yahoo Finance 28 Jan 2024